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Background: Alterations in glucose metabolism and epithelial-mesenchymal transition (EMT) constitute two important
characteristics of carcinoma progression toward invasive cancer. Despite an extensive characterization of each of them
separately, the links between EMT and glucose metabolism of tumor cells remain elusive. Here we show that the
neuronal glucose transporter GLUT3 contributes to glucose uptake and proliferation of lung tumor cells that have
undergone an EMT.
Results: Using a panel of human non-small cell lung cancer (NSCLC) cell lines, we demonstrate that GLUT3 is strongly
expressed in mesenchymal, but not epithelial cells, a finding corroborated in hepatoma cells. Furthermore, we identify
that ZEB1 binds to the GLUT3 gene to activate transcription. Importantly, inhibiting GLUT3 expression reduces glucose
import and the proliferation of mesenchymal lung tumor cells, whereas ectopic expression in epithelial cells sustains
proliferation in low glucose. Using a large microarray data collection of human NSCLCs, we determine that GLUT3
expression correlates with EMT markers and is prognostic of poor overall survival.
Conclusions: Altogether, our results reveal that GLUT3 is a transcriptional target of ZEB1 and that this glucose
transporter plays an important role in lung cancer, when tumor cells loose their epithelial characteristics to become
more invasive. Moreover, these findings emphasize the development of GLUT3 inhibitory drugs as a targeted therapy
for the treatment of patients with poorly differentiated tumors.
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The reprogramming of energy metabolism constitutes
one of the hallmarks of cancer [1]. In order to build the
necessary biomass required for proliferation, tumor cells
increase their glucose consumption [2]. Glucose trans-
porters of the GLUT (SLC2A) family are at the first step
of cellular glucose utilization, mediating glucose entry by
facilitative diffusion. The GLUT family is composed of
14 members that transport glucose or other substrates
in different tissues, with different efficiencies [3]. In vari-
ous tumor types, an increased expression of GLUT1 has
been reported [4]. Furthermore, GLUT1 levels are higher* Correspondence: etienne.meylan@epfl.ch
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mutations compared with isogenic clones and confer cell
survival properties in low-glucose conditions [5]. Interest-
ingly, in an oncogenic Kras(G12D)-dependent mouse
model of pancreatic ductal adenocarcinoma (PDAC),
oncogene withdrawal led to reduced Glut1 expression and
glucose uptake [6]. In contrast to GLUT1, little is known
about the regulation and function of another glucose
transporter, GLUT3, in cancer. GLUT3 was originally re-
ferred to as the neuronal GLUT [7]; with a high affinity
for glucose (KM approximately 1.5 mM) and the highest
calculated turnover number of all glucose transporters, it
ensures efficient glucose uptake by neurons of the central
nervous system. With the exception of neurons and a few
hematopoietic cell types, GLUT3 is lowly or not expressed
in most organs of healthy adults. However, pathologicaltd. This is an Open Access article distributed under the terms of the Creative
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ovarian, and non-small cell lung cancer (NSCLC) [8,9].
Recently, GLUT3 was shown to be highly expressed in
glioblastoma and to promote the growth of brain tumor
initiating cells [10]. GLUT3 was also reported to be a tran-
scriptional target of NF-κB and HMGA1, in mouse em-
bryonic fibroblasts and human colorectal tumor cells,
respectively [11,12]. However, the regulation and con-
tribution of GLUT3 to lung tumor progression remain
unknown.
The epithelial-mesenchymal transition (EMT) is a
process that occurs early in embryonic development,
notably during gastrulation, in which epithelial cells
undergo cytoskeletal changes and lose cell-cell contacts
to gain mesenchymal traits and become more motile
[13]. During carcinoma progression, pathological EMT
occurs to promote tumor cell invasion and metastasis.
One of the essential steps in the EMT process is the loss
of E-cadherin, an adherens junction protein that main-
tains cell-cell adhesion and epithelial tissue integrity.
Mechanistically, the EMT process can be triggered by
different transcription factors that include TWIST,
ZEB1, ZEB2, SNAIL, and SLUG [14]. In our study, we
discovered a strong association between the EMT pro-
gram and the induction of the glucose transporter
GLUT3 in NSCLC and extended this observation to
tumor cells from another cancer type, hepatocellular car-
cinoma (HCC). We demonstrate that GLUT3 is a direct
transcriptional target of ZEB1. We further show that
GLUT3 expression contributes to proliferation of lung
tumor cells and is an independent prognostic factor of
poor overall survival in NSCLC.
Methods
Plasmid constructs
Human GLUT3, mouse Snail, and mouse Zeb1 cDNAs,
purchased from Thermo Scientific (Waltham, MA, USA;
MHS1010-7429646, MMM1013-7510291, and MMM1013-
99828709, respectively), were amplified by polymerase
chain reaction (PCR) using forward 5′-CTCATCGATGC
CACCATGGGGACACAGAAGGT-3′ and reverse 5′-CT
CCCCGGGTTAGACATTGGTGGTGG-3′ (GLUT3), for-
ward 5′-CTCATCGATGCCACCATGCCGCGCTCCTTC-
3′ and reverse 5′-CTCGAATTCTCAGCGAGGGCCT
CC-3′ (Snail), and forward 5′-CTCATCGATGCCACCAT
GGCGGATGGCCCC-3′ and reverse 5′-CTCGAATTCCT
AAGCTTCATTTGT-3′ (Zeb1) oligos. The PCR products
were digested with ClaI and XmaI (GLUT3) or ClaI and
EcoRI (Snail and Zeb1) and cloned into identically
digested pRDI292-CMV lentiviral vector (gift of D. Trono,
EPFL, Lausanne). Genomic DNA was used to amplify by
PCR (a) an approximately 1,000-bp region ending
close to the transcription start site of human SLC2A3
(gene encoding GLUT3), with the oligos forward 5′-CTCGAGCTCGAGACTAGCAGAAAGTG-3′ and re-
verse 5′-CTCCTCGAGCGACAAGCCCCCAGCCCCAC
CCCACCCCACCCCACCCCCCTGAAGCAA-3′, or (b)
a region containing the SLC2A3 intron 2 sequence, with
the oligos forward 5′-CTCGAGCTCACTGGGGTCAT
CAATGCTCC-3′ and reverse 5′-CTCCTCGAGGGTTG
GTGGAAGAACAGAC-3′. After SacI and XhoI diges-
tion, the fragments were cloned into an identically
digested luciferase reporter plasmid containing a minimal
promoter (kindly provided by J. Huelsken, EPFL, Lausanne)
to generate prom.-LUC or int.2-LUC constructs, respect-
ively. Deletion of the E-box-like motif CACCTC from the
intron 2 sequence was achieved by site-directed mutagen-
esis, using oligos forward 5′-CCACTCTTTATAGTGA
TGCACATCCTG-3′ and reverse 5′-CATCACTATAAA
GAGTGGGAGGAAGAAC-3′, combined with the oligos
indicated above in (b). shRNAs specific to GLUT3 were
either from Thermo Scientific (TRCN0000042880) or
designed using the pSICOLIGOMAKER 1.5 program
(created by A. Ventura, Memorial Sloan-Kettering Can-
cer Center, New York). In the latter case, forward 5′-
TGCAAGGATGTCACAAGAAATTCAAGAGATTTCT
TGTGACATCCTTGCTTTTTTC-3′ and reverse 5′-TC
GAGAAAAAAGCAAGGATGTCACAAGAAATCTCT
TGAATTTCTTGTGACATCCTTGCA-3′ oligos were
annealed and ligated into a pSicoR lentiviral vector.
The fidelity of all the PCR amplifications and oligo
syntheses was confirmed by sequencing. Control pLKO.1
was from Thermo Scientific.Immunoprecipitation
Cells (8 × 107 per immunoprecipitation) were lysed in
NP-40 buffer (0.2% NP-40, 150 mM NaCl, 20 mM Tris
pH 8.0, 10 mM EDTA) containing a protease inhibitor
cocktail (complete, Roche, Basel, Switzerland) and 1 mM
Na3VO4 for 15 min on ice, followed by three quick steps
of freezing in liquid N2 and thawing at 37°C. Pre-clearing
was achieved using sepharose-6B (Sigma-Aldrich, St.
Louis, MO, USA) for 60 min at 4°C on a rotating wheel.
Immunoprecipitation was performed using a 1:1 mixture
of sepharose-6B and protein-G sepharose (Sigma-Aldrich),
together with 2 μg control or ZEB1 antibody, overnight at
4°C on a rotating wheel. After four steps of washing in
lysis buffer, sample buffer was added, and the samples
were boiled and loaded on a polyacrylamide gel for elec-
trophoresis followed by Western blot.Western blotting
Except when used for immunoprecipitation, cells were
lysed in RIPA buffer (20 mM Tris pH 8, 50 mM NaCl,
0.5% Na-deoxycholate, 0.1% SDS, 1 mM Na3VO4, prote-
ase inhibitor cocktail (complete, Roche)) for 5 min on
ice. Proteins were loaded on 8% or 10% polyacrylamide
Masin et al. Cancer & Metabolism 2014, 2:11 Page 3 of 14
http://www.cancerandmetabolism.com/content/2/1/11gels for electrophoresis (150 V, 1 h). Transfer was per-
formed on PVDF membranes (100 V, 1 h).
Cell culture conditions
The human embryonic kidney (HEK) 293 T cells and the
human hepatoma cell lines, which include HLF, HLE,
Huh-1 (all three kindly provided by K. Morikawa, Showa
University, Tokyo, Japan), Huh-7, and Hep3B, were
grown in DMEM. The human non-small cell lung can-
cer cell lines include A549, SW1573, NCI-H23, NCI-
H2122, NCI-H441, NCI-H460, NCI-H727, NCI-H2009,
NCI-H1944, and Calu-6; they were all obtained from
ATCC (Manassas, VA, USA) and all grown in RPMI. All
cell media were supplemented with 10% FBS. For the ex-
periments with high or low glucose, cells were cultured
for 4 days in normal RPMI (containing 11 mM glucose),
supplemented by 10% FBS, or with RPMI without glu-
cose, supplemented by 10% FBS, resulting in a final con-
centration of 11.5 mM and 0.5 mM glucose, respectively.
After 2 days of culture, the medium was replaced with
fresh medium to maintain the initial concentrations of
glucose.
Cell counting
To measure cell number, a trypan blue exclusion assay
was performed. Cells were mixed with trypan blue, and
the number of live, dead, and total cells was counted on
an automated cell counter (Countess, Life Technologies,
Carlsbad, CA, USA).
2-Deoxy-D-[3H]glucose uptake
Cells (1 × 106 per well, seeded the day before the experi-
ment) were cultured on six-well plates. 2-Deoxyglucose
uptake assays were performed as described previously
[15]. Radioactivity was determined by scintillation count-
ing. For sample normalization, protein concentration
was measured by BCA protein assay.
Transfection
siRNAs were from Life Technologies. siRNA transfection
was performed with RNAiMAX transfection reagent
(Life Technologies), according to the manufacturer’s
instructions. For each siRNA, 10 nM was used. cDNA
transfection of 293 T cells was performed with Lipofec-
tamine 2000 (Life Technologies), according to the manu-
facturer’s instructions. For each well of a 12-well plate, a
mix of 125 ng Renilla-Luciferase (phRL-TK, Promega,
Madison, WI, USA) and 1.6 μg GLUT3-Luciferase (pro-
moter, intron 2-WT or intron 2-Δ-CACCTC) was used.
Twenty-four hours after transfection, cells were lysed
and a luciferase reporter assay was performed (Dual-
Luciferase Reporter Assay System, Promega). The re-
ported luciferase activity was the ratio between Firefly
(GLUT3 construct)-Luciferase and Renilla-Luciferase,which was then normalized to 1 to get fold activities.
For double transfection, 293 T cells were transfected first
with siRNAs and re-transfected 72 h later with plasmids,
24 h prior to lysis.
Anchorage-independent growth assays
Cells (9 × 104) were plated in triplicates in six-well
plates in 0.4% agar in RPMI on top of a layer of 0.8%
agar with RPMI. Cells were allowed to grow at 37°C
for 3 weeks. Colonies were counted using a micro-
scope. A colony was defined as an aggregate of 50 or
more cells.
RNA purification, reverse transcription, and real-time PCR
amplification
RNA was purified using Trizol (Life Technologies), ac-
cording to the manufacturer’s instructions. RNA (1 μg)
was reverse-transcribed using the High-Capacity cDNA
Reverse Transcription Kit (Life Technologies). cDNA
(5 ng) was used for real-time PCR amplification, using
commercially available Taqman probes for human 18S,
GAPDH, SLC2A3, SLC2A1, SLC2A4, SLC2A12, VIM,
ZEB1, SNAI1, and CDH1 (Life Technologies). Data were
normalized to GAPDH or 18S levels. For measurement of
mature miR-200b, reverse transcription was performed
with the TaqMan MicroRNA Reverse Transcription Kit
(Life Technologies), according to the manufacturer’s in-
structions, separately for miR-200b and the normalization
control, RNU24. cDNA (0.9 ng) was used for real-time
PCR amplification.
Immunocytochemistry
Cells (4 × 107) were fixed in 4% paraformaldehyde, em-
bedded in paraffin, and mounted on slides. Following
antigen retrieval with 10 mM Na-citrate and blocking,
cells were stained with anti-GLUT3 or anti-E-cadherin
antibodies overnight at 4°C, followed by washing and
staining with biotin-conjugated secondary antibodies for
1 h at room temperature. After washing, avidin-biotin
horseradish peroxidase complexes were added for 30 min
(ABC kit, Vectastain), and the complexes were revealed
with a DAB peroxidase substrate kit (Vector Laboratories,
Burlingame, CA, USA). Counterstain was performed using
Harris hematoxylin.
Reagents
Recombinant human TGF-β2 was from PeproTech
(Rocky Hill, NJ, USA). Antibodies used were anti-GLUT3
(#400062, Calbiochem, San Diego, CA, USA), anti-E-
cadherin (#3195, Cell Signaling Technology, Danvers,
MA, USA), anti-vimentin (#5741, Cell Signaling), anti-
SNAIL (#3879, Cell Signaling), anti-ZEB1 (#sc-25388,
Santa Cruz Biotechnology, Inc., Dallas, TX, USA), anti-β-
tubulin (#sc-9104, Santa Cruz Biotechnology), anti-CtBP
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585, Santa Cruz Biotechnology), and normal rabbit IgG
(#12-370, Millipore, Billerica, MA, USA).
Virus production and infection
293 T cells were transfected using the calcium-phosphate
precipitation method, co-transfecting the lentiviral plas-
mid of interest in conjunction with pMD2G (VSV-G pro-
tein) and pCMVR8.74 (lentivirus packaging vector, kind
gift of D. Trono, EPFL, Lausanne). Viral supernatants
were harvested 24 and 36 h post-transfection, filtered,
and used directly for infection of cell lines, as de-
scribed. Puromycin selection was performed to select
cells with stable pRDI292-CMV (delivering control, hu-
man GLUT3, mouse Snail, or mouse Zeb1 cDNA) or
pLKO.1 (with control or GLUT3 shRNA) genomic inte-
gration. Fluorescence-activated cell sorting was used to
select cells with stable pSicoR constructs, based on GFP
expression.
Statistics
Unless specified differently, P values were determined by
Student’s t tests.
ChIP-seq analysis
Publicly available replicate ChIP-seq data for ZEB1
(GSM803411), RNA polymerase II (GSM803485), H3K27ac
(GSM733771), as well as naked DNA (Input) (GSM733742)
[16] were re-analyzed using Bowtie 2 [17] for mapping
to the human GRCh37 genome with the parameters
‘–very-sensitive -M 10 -p 8’ and CCAT 3.0 [18] for
peak-calling using the parameters ‘fragmentSize 200 sli-
dingWinSize 100 movingStep 50 isStrandSensitiveMode
1 minCount 13 outputNum 100000 randomSeed 123456
minScore 5 bootstrapPass 80’. Data were visualized using
IGV Browser [19].
ChIP-PCR
ChIP was performed as described previously [20], using
6 × 107 SW1573 and 5 μg of each antibody. To amplify
regions within the promoter region of SLC2A3, the fol-
lowing primers were used: 5′-ACTGCCCTGATAGTT
GGTCTGG-3′ with 5′-TTTGCCAGTGTTCCTTTCTT
CG-3′ (−608 and −523 bp upstream of SLC2A3 TSS); 5′-
ACTGCCCTGATAGTTGGTCTGG-3′ with 5′-GAGG
GAAAGACAGCCTGAGAGA-3′ (−608 and −482 bp
upstream of SLC2A3 TSS). To amplify regions from the
intron 2, the following primers were used: 5′-CATCA
CAGTTGCTACAATCGGC-3′ with 5′-ACCATGCCTG
GCCTTAAATTCT-3′ (2,396 and 2,559 bp downstream
of SLC2A3 TSS); 5′-ACCATGCCTGGCCTTAAATT
CT-3′ with 5′-AGCCTCAGGAGTAGCTGGGACT-3′
(2,452 and 2,594 bp downstream of SLC2A3 TSS); 5′-
GTGAGTGCCAGGCCACAATAAT-3′ with 5′-TGTGTTGCTCAGGATGGTGTTT-3′ (2,466 and 2,647 bp
downstream of SLC2A3 TSS); 5′-AGTCCCAGCTAC
TCCTGAGGCT-3′ with 5′-TTCCGGGAGTAAGTG
AGCTTTG-3′ (2,573 and 2,791 bp downstream of
SLC2A3 TSS); 5′-AAACACCATCCTGAGCAACACA-
3′ with 5′-TGAGGTGAAAGAGTGGGAGGAA-3′ (2,626
and 2,831 bp downstream of SLC2A3 TSS); 5′-TTCCT
CCCACTCTTTCACCTCA-3′ with 5′-GCACCGATGTT
CACAGTCTACC-3′ (2,810 and 2,926 bp downstream of
SLC2A3 TSS); 5′-AAGCTGGGTTCCCTTAGCAGAG-3′
with 5′-AAAGGGTTGGTGGAAGAACAGA-3′ (2,877
and 3,117 bp downstream of SLC2A3 TSS); 5′-CAGT
CTGTTCTTCCACCAACCC-3′ with 5′-AGGACCAGA
GAGACGTGAGCAG-3′ (3,093 and 3,212 bp down-
stream of SLC2A3 TSS). The intergenic region upstream
of GAPDH was amplified, using primers 5′-ATGGGTGC
CACTGGGGATCT-3′ and 5′-TGCCAAAGCCTAGGG
GAAGA-3′, as described previously [21]. As positive con-
trol, a DNA sequence of CDH1 known to bind ZEB1 was
amplified using primers 5′-GGCCGGCAGGTGAACCC
TCA-3′ and 5′-GGGCTGGAGTCTGAACTGA-3′, as
described previously [22]. Real-time PCR was performed
using SyBR green. Fold enrichment was calculated as
follows: 2^ΔΔct (ΔΔct =Δctspecific antibody −ΔctIgG). Data
were normalized using the negative control, an un-
transcribed region upstream of GAPDH, and represented
as fold enrichment/fold enrichment of the negative con-
trol locus.
Microarray analysis
We collected publicly available datasets from journal arti-
cles and Gene Expression Omnibus (GEO) repository,
selecting those with medium to large sample size [23,24].
The .CEL files were imported into R/Bioconductor (http://
www.bioconductor.org/) and RMA normalized [25]. A
total of 462 early-stage untreated lung NSCLC samples
were available, with associated patients’ overall survival.
The probe IDs with higher variation for each gene were
retained from a total of 13,960 genes. The normalized data
together with the clinico-pathological variables were then
used for further analysis. Pairwise Spearman correlations
between GLUT3 and other available genes were calcu-
lated. Univariate and multivariate survival analyses were
performed using proportional Cox regression (package
‘survival’, R). Kaplan-Meier figure was reported showing
hazard ratio (HR), 95% confidence intervals, and Wald
p_value from Cox regression model for a specific com-
parison of interest. The continuous GLUT3 expression
was dichotomized in high and low risk levels by the
median of the expression for visualization purposes.
Multivariate analysis was performed with the following
variables: GLUT3 continuous expression, stage, hist-
ology, gender, and age (dichotomized by the median of
62 years).
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GLUT3 expression correlates with EMT
To determine if the neuronal glucose transporter GLUT3
is expressed in lung tumor cells, we used a panel of ten
human NSCLC cell lines. We noticed that GLUT3 expres-
sion, as determined by real-time PCR analysis, varied con-
siderably between the cell lines, with five of them
expressing high and the other five expressing low GLUT3
mRNA levels (Figure 1A). Several molecular markers can
be used to classify human lung tumor cells according to
their EMT status [26]. We monitored the epithelial or
mesenchymal status in these cells by assessment of RNA
levels of E-cadherin and the mature form of miR-200b0
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GLUT3, or if other transporters within this family had a
similar expression pattern, we monitored the expression
of additional GLUT family members that carry glucose
(GLUT1, GLUT2, GLUT4, GLUT12, and GLUT14).
Whereas GLUT2 and GLUT14 were undetectable across
the cell lines (MM and EM, unpublished observations),
GLUT1, GLUT4, and GLUT12 were expressed, but none
of them showed any correlation with EMT (Additional
file 1). Next, to confirm that high GLUT3 mRNA ex-
pression in mesenchymal cells reflected actual protein
expression, we performed immunocytochemistry analyses.
This demonstrated that GLUT3 protein was expressed
and localized to the plasma membrane of mesenchymal
cells, but was not detectable in the cells from the epithelial
group (Figure 1B); once again, there was an inverse correl-
ation between GLUT3 and E-cadherin expression.
GLUT3 is induced during EMT
To test the hypothesis that GLUT3 is induced upon
EMT, we first stimulated the H2122 epithelial cell line
with TGF-β, a potent EMT-inducing factor. As expected, 
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human ZEB1 and GLUT3 mRNA, respectively, whereas it
was 9- and 354-fold in H2009 cells (Additional file 2).
Next, to assess if the link between GLUT3 and EMT is
specific for NSCLC, or whether it occurs in other tumor
types, we analyzed GLUT3 expression in human cell lines
derived from HCC. Based on marked differences in the
expression of vimentin and E-cadherin, we could distin-
guish two groups of cells: an epithelial group (Huh-7,
Hep3B, and Huh-1) and a mesenchymal group (HLF and
HLE). Similar to NSCLC cell lines, GLUT3 but not
GLUT1 expression was specifically elevated in the mes-
enchymal group, and very low in the epithelial group
(Figure 3A). Additionally, TGF-β treatment of the low-
GLUT3 expressing cell line, Hep3B, led to increased ex-
pression of GLUT3, whereas GLUT1 levels remained
unchanged (Figure 3B). Altogether, these data demon-
strate that the regulation of GLUT3 during EMT occurs
in at least two different cancer types, NSCLC and HCC.
ZEB1 induces GLUT3 through direct binding and
transcriptional activation
Although ZEB1 is best characterized as a transcriptional
repressor, depending on co-factor recruitment—and
probably other parameters—it can activate transcription.
For example, ZEB1 represses gene transcription when
bound to the co-repressor C-terminal-binding protein
(CtBP), whereas it activates target gene expression
when bound to p300, P300/CBP-associated factor
(P/CAF), or receptor-regulated (R)-SMADs [29-32].
Co-immunoprecipitation experiments performed on ex-
tracts from mesenchymal lung tumor cells revealed en-
dogenous interactions between ZEB1 and CtBP, as well as
ZEB1 and p300, suggesting ZEB1 forms different com-
plexes to trigger target gene repression or activation in
these cells (Additional file 3). To test the hypothesis that
ZEB1 directly activates GLUT3 (SLC2A3) gene transcrip-
tion, ZEB1 mRNA and protein expression was first moni-
tored in the panel of lung tumor cells. This showed that
ZEB1 was more strongly expressed in GLUT3-proficient,
mesenchymal cells compared to cells from the epithelial
group (Figure 4A and Additional file 1). Additionally, in
response to TGF-β stimulation (see Figure 2A), there was
an up-regulation of ZEB1, but not SNAIL, which preceded
that of GLUT3 (Additional file 4), suggesting ZEB1 induc-
tion enables the activation of GLUT3 transcription. Next,
we analyzed public data from lymphoblastoid cell extracts
subjected to chromatin immunoprecipitation using anti-
ZEB1, anti-RNA polymerase II or anti-histone H3 (acetyl
K27) antibodies, followed by DNA sequencing (ChIP-seq)
[16]. SLC2A3 was actively transcribed in these cells, as in-
ferred from the occupancy of RNA polymerase II and the
acetylation of histone H3 on Lysine 27 at the SLC2A3
locus (Figure 4B). Importantly, an interaction betweenZEB1 and a region located within the second intron of
SLC2A3 was uncovered, with a peak of interaction that lo-
calized to an E-box-like motif, composed of a CACCTC
sequence (Figure 4B). Of note, ZEB1 has been reported to
bind such DNA sequences to regulate transcription
[33,34]. To determine if a similar ZEB1-SLC2A3 gene
interaction occurred in GLUT3-expressing lung tumor
cells, we performed ChIP-PCR analyses in extracts of
SW1573 cells. As positive and negative controls, respect-
ively, we amplified a sequence of E-cadherin (CDH1)
known to bind ZEB1 and an intergenic sequence up-
stream of GAPDH [21,22]. ZEB1 bound to DNA se-
quences located within intron 2 of SLC2A3, but not to
sequences from the promoter region (Figure 4C). Having
established the localization of ZEB1 binding to the
SLC2A3 gene, we cloned the DNA sequence of intron 2
or, for comparison, a 1-kb sequence preceding the
SLC2A3 transcription start site into a luciferase reporter
plasmid (Figure 4D). Upon transfection into 293 T cells,
which express high amounts of endogenous ZEB1 (see
Figure 4A), the basal luciferase activity was significantly
stronger from the intron 2 construct than from the pro-
moter construct. Also, luciferase activity from the intron 2
construct significantly decreased upon ZEB1 knockdown
(Figure 4D). Furthermore, deletion of the E-box-like motif
in intron 2 substantially reduced luciferase activity, reveal-
ing the CACCTC sequence as an important functional
element in response to ZEB1 (Figure 4E). Collectively,
these results demonstrate that GLUT3 is induced during
EMT by a mechanism involving direct binding and tran-
scriptional activation by ZEB1.
GLUT3 promotes glucose uptake and proliferation of
mesenchymal lung tumor cells
We next sought to determine the functional conse-
quences of high GLUT3 expression in mesenchymal
lung tumor cells using GLUT3 knockdown. Transfection
of small interfering (si)RNAs to GLUT3 into SW1573
cells caused a reduction in the number of live cells,
whereas GLUT1 knockdown did not or only slightly re-
duced cell number (Figure 5A and Additional file 5).
The proportion of dead cells was not changed upon
GLUT3 knockdown in SW1573 cells (Additional file 5),
suggesting that GLUT3 primarily regulates proliferation
of these cells, not survival. In contrast, H727, a low-
GLUT3 expressor, was not affected by GLUT3 knock-
down. Next, we transduced SW1573 cells with lentiviruses
delivering short hairpin (sh)RNAs targeting GLUT3 to
generate cells with stable GLUT3 knockdown (Additional
file 5). We first used these cells to interrogate the contri-
bution of GLUT3 to glucose import. Knockdown of
GLUT3 with two independent shRNAs led to a decrease
of more than 50% in the efficiency of radioactive 2-
deoxyglucose incorporation, revealing that GLUT3 plays a
A
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http://www.cancerandmetabolism.com/content/2/1/11prominent role in glucose uptake of mesenchymal cells
(Figure 5B). Importantly, GLUT3 knockdown also led to
a reduction in the number of colonies grown in
anchorage-independent conditions (Figure 5C). Next, todetermine if GLUT3 knockdown had an impact on the
mesenchymal state of tumor cells, we monitored vimen-
tin and E-cadherin expression. Interestingly, vimentin
expression was substantially decreased upon GLUT3
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(See figure on previous page.)
Figure 4 GLUT3 is a direct ZEB1-target gene. (A) The indicated cell lines were lysed with RIPA buffer to prepare protein extracts and to
analyze the expression of ZEB1, or β-tubulin as control, by Western blot. (B) IGV Browser view of 33 kb around the SLC2A3 gene including ZEB1
(black), RNA Polymerase II (RNAPolII, green), the active histone mark H3K27ac (green-yellow) ChIP-seq, and Input (grey) tracks in human lymphoblastoid
cell lines. ZEB1 peak calls and ‘CACCTC’ sequence matches on the reverse strand are also indicated (black). The orientation of SLC2A3 is indicated by an
arrow. (C) Extracts from SW1573 cells were used for ZEB1 ChIP followed by real-time PCR. The coordinates of the PCR amplicons relative to the TSS are
indicated. CDH1 and an untranscribed sequence upstream of GAPDH were used as positive and negative controls for ZEB1 binding, respectively. The
data shown are representative of three independent experiments. (D) (Upper part) scheme showing the promoter region of 1,000 bp preceding the
transcription start site (prom.) and the intron 2 region (int.2), which were amplified from the SLC2A3 gene and cloned into the luciferase reporter
construct. Ex. exon, LUC luciferase. (Lower part) 293 T cells were transfected with the indicated luciferase reporter plasmids. Luciferase activity was
analyzed 24 h later. Data show means ± s.d. (n = 5) of relative luciferase activity. (Lower right) 293 T cells were transfected with control (ctl) or ZEB1
siRNAs and were lysed 96 h later to prepare protein extracts and to analyze the expression of ZEB1, or β-tubulin as control, by Western blot. (E) 293 T
cells were transfected with the indicated luciferase reporter plasmids. For the int.2 construct, either wild-type (WT) or a variant with a deletion of the
E-box-like motif (Δ-CACCTC) was used. Luciferase activity was analyzed 24 h later. Data show means ± s.d. (n = 5) of relative luciferase activity.
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http://www.cancerandmetabolism.com/content/2/1/11knockdown (Additional file 6). Hence, although we did
not observe any statistically significant variation in E-cad-
herin mRNA levels, these data suggest that GLUT3-
dependent glucose uptake participates in the maintenance
of a mesenchymal state. Finally, we wanted to determine if
increased GLUT3 expression is sufficient to impact on the
growth of lung tumor cells with epithelial traits. To do
this, we generated H727 cells stably expressing human
GLUT3 (Additional file 7). In high glucose concentrations,
there was no difference in the proliferation of cells overex-
pressing GLUT3 and control cells (Additional file 7).
However, we reasoned that because parental H727 cells
have adapted to grow in high glucose levels without
GLUT3, ectopic expression of this high-affinity glucose
transporter might affect proliferation specifically when
glucose concentrations are low. Indeed, the growth rate of
parental cells was diminished by a reduction in glucose
levels. Under these conditions, H727-GLUT3 cells grew
faster than control cells, demonstrating that GLUT3 ex-
pression is sufficient to increase cancer cell proliferation
in conditions where glucose concentrations are limiting
(Figure 5D). Altogether, these results demonstrate an im-
portant contribution for GLUT3 in lung tumor cell
proliferation.
GLUT3 expression in human NSCLC correlates with poor
overall survival and EMT signatures
To assess the relevance of our findings in vivo, we used
a combination of five publicly available microarray data-
sets of human NSCLC. This yielded 462 samples with
follow-up of overall survival. The analysis revealed that
high GLUT3 expression was associated with a poor over-
all survival (Figure 6A), a finding consistent with previ-
ous studies [10,35]. Additionally, a multivariate analysis
provided evidence for high GLUT3 expression as an in-
dependent predictor of poor overall survival (Table 1).
Next, we made pairwise comparisons between each of
SLC2A3, CDH1, and various EMT markers or inducers
(VIM, SNAI1, SNAI2, ZEB1, ZEB2, and TWIST1). As
expected, most mesenchymal genes had a positivecorrelation with each other and a negative correlation
with CDH1. Importantly, all mesenchymal genes showed
a statistically significant positive correlation with
SLC2A3 expression (P < 0.001) (Figure 6B). SLC2A3 ex-
pression was also negatively correlated with CDH1, as
expected, although these data were not significant
(Figure 6B). Altogether, these in vivo findings support the
in vitro data that position GLUT3 as an important factor
in the process of EMTand lung tumor progression.
Discussion
In this study, we have identified a unique role for glu-
cose transporter GLUT3 in the proliferation of lung
tumor cells with mesenchymal characteristics. We found
that GLUT3 is strongly up-regulated during EMT and con-
tributes to glucose uptake specifically in mesenchymal-like
lung tumor cells. Furthermore, GLUT3 overexpression is
sufficient to substantially enhance the proliferation of lung
tumor cells with epithelial traits specifically in the context
of low glucose. Interestingly, increased glucose consump-
tion was shown to promote EMT via stabilization of
SNAIL [36], suggesting that increased expression of
GLUT family members promotes the induction and/or
maintenance of EMT. In our experiments, we did not de-
tect an EMT occurring in response to ectopic GLUT3
protein expression in epithelial cells (MM and EM, un-
published observations), but we found a decrease in
vimentin expression upon GLUT3 knockdown in mesen-
chymal cells. Collectively, these data suggest the intriguing
possibility that GLUT3 plays a role in the successful estab-
lishment or maintenance of the EMT, when tumor cells
become more motile and invasive, or in tumor cell sur-
vival upon loss of cell-cell adhesion.
EMT in cancer is a complex phenomenon that is or-
chestrated by different transcription factors with partially
overlapping gene targets. These transcription factors,
like SNAIL or ZEB1, often act as transcriptional repres-
sors. However, the mechanisms of target gene regulation
are not fully elucidated. For example, ZEB1 inhibits the
transcription of target genes when bound to CtBP
AB
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Figure 5 GLUT3 promotes glucose uptake and the proliferation of mesenchymal lung tumor cells. (A) Mesenchymal (SW1573) or epithelial
(H727) cells were transfected with control (ctl) siRNA, each of three different siRNAs to decrease GLUT3, or each of two siRNAs to decrease GLUT1, as
indicated. One hundred forty-four hours later, live cells were counted by trypan blue exclusion (n= 3 or 4). (B) 2-Deoxy-D-[3H]glucose (DOG) incorporation
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A BOS - GLUT3
Figure 6 GLUT3 expression correlates with poor overall survival and EMT in human NSCLC. (A) Kaplan-Meier plot representing overall
survival comparing tumor samples with high or low GLUT3 levels. The numbers of living patients are indicated for each year and group. HR hazard
ratio, OS overall survival. (B) The correlations between each of GLUT3 (SLC2A3), E-cadherin (CDH1), SNAIL (SNAI1), SLUG (SNAI2), Twist (TWIST1),
vimentin (VIM), ZEB1, and ZEB2 were assessed from the pooled dataset. Spearman correlation coefficients (indicated numbers) were calculated
between the expression values of each pair. 0.1 < P < 0.05; *P < 0.05; **P < 0.01; ***P < 0.001.
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http://www.cancerandmetabolism.com/content/2/1/11[29,31]. In contrast, ZEB1 binding to R-SMADs and the
acetyltransferases p300 and P/CAF promotes target gene
transcription [30,32]. Likewise, in our study, we have
demonstrated that ZEB1 can interact with each of CtBP
and p300 in mesenchymal lung tumor cells and that it is
a direct activator of SLC2A3 gene transcription. Of note,
ZEB1 expression was higher in the mesenchymal,
GLUT3-expressing cell lines compared to the epithelial
cell lines, and ZEB1 was induced prior to GLUT3 in re-
sponse to TGF-β (see Figures 2A and 4A, and AdditionalTable 1 Univariate and multivariate analyses of overall
survival in NSCLC
HR Lower 0.95 Upper 0.95 P value
(Wald)
Univariate
SLC2A3 (continuous) 1.224 1.047 1.432 1.14E − 02
Stage (II vs. I) 1.590 1.070 2.363 2.19E − 02
Histology LCC vs. AD 1.131 0.458 2.792 7.89E − 01
Histology SCC vs. AD 1.624 1.150 2.293 5.91E − 03
Gender (F vs. M) 0.610 0.429 0.868 6.06E − 03
Age (>62 vs. ≤62) 1.906 1.385 2.622 7.47E − 05
Multivariate
SLC2A3 (continuous) 1.194 1.016 1.404 3.16E − 02
Stage (II vs. I) 1.432 0.945 2.170 9.04E − 02
Histology LCC vs. AD 1.006 0.406 2.495 9.90E − 01
Histology SCC vs. AD 1.552 1.071 2.248 2.03E − 02
Gender (F vs. M) 0.702 0.484 1.020 6.33E − 02
Age (>62 vs. ≤62) 1.829 1.323 2.528 2.56E − 04
AD adenocarcinoma, F female, HR hazard ratio, LCC large cell carcinoma, M male,
SCC squamous cell carcinoma.files 1 and 4). This is in agreement with a previous
finding reporting that the SLC2A3 gene was one of the
top 50 genes correlating positively with ZEB1 gene ex-
pression in a panel of human lung tumor cell lines
[37]. In the future, it will be important to decipher all
of the genes that are directly targeted—either repressed
or induced—by ZEB1 in lung cancer and to determine
if this includes additional genes that regulate tumor cell
metabolism.
The increased GLUT3 expression observed in tumor
cells upon EMT may have important implications for
cancer treatment. Indeed, not only is EMT well recog-
nized as a crucial process that increases invasive capaci-
ties of tumor cells and promotes the acquisition of stem
cell characteristics [38], it may occur earlier in tumor de-
velopment than previously anticipated. For example, in a
K-rasLSL-G12D/+; p53Flox/Flox mouse model of PDAC,
EMT and invasiveness precede the detection of tumors
in situ [39]. Interestingly, a molecular classification of
human PDAC was performed recently, where three sub-
types were defined: classical, exocrine-like, and quasi-
mesenchymal (which has the worst prognosis of all
three) [40]; SLC2A3 was one of a 20-gene signature of
the quasi-mesenchymal subtype. This observation, to-
gether with our findings of a connection between
GLUT3 and EMT in human liver cells from HCC, indi-
cates that the regulation of GLUT3 by EMT extends be-
yond lung cancer.
Conclusions
By uncovering direct regulation of GLUT3 by the tran-
scription factor ZEB1, our study provides evidence for a
tight association between two central characteristics of
Masin et al. Cancer & Metabolism 2014, 2:11 Page 13 of 14
http://www.cancerandmetabolism.com/content/2/1/11carcinoma development: EMT and glucose metabolism.
Because GLUT3 expression is mainly restricted to the
brain of healthy individuals, the future development of
small molecule compounds that selectively block
GLUT3 and that do not cross the blood-brain barrier
may become a viable strategy to treat patients with
NSCLC and possibly other cancer types.
Additional files
Additional file 1: Figure S1. GLUT1, GLUT4, GLUT12, and ZEB1
expression in mesenchymal and epithelial lung tumor cells. The indicated
cell lines were lysed for RNA preparation followed by reverse transcription.
The cDNA was amplified by real-time PCR using probes specific for the
indicated genes or internal controls. Data show means ± s.d. (n = 3) of
mRNA expression relative to the cell line expressing the least amount of the
same gene (set to 1). When there was no specific amplification after
40 cycles of PCR, the samples were called not determined (N.D.).
Additional file 2: Figure S2. hZEB1 and hGLUT3 induction upon
mSNAIL overexpression. H727 or H2009 cell populations stably expressing
a control plasmid (ctl) or mouse (m) SNAIL were lysed for RNA preparation
followed by reverse transcription. The cDNA was amplified by real-time PCR
using probes specific for human ZEB1, GLUT3, or an internal control. Data
show means ± s.d. (n = 3) of mRNA expression, represented as fold
induction (mSNAIL/ctl) for each cell line. The arrows and numbers indicate
the fold induction between samples.
Additional file 3: Figure S3. ZEB1 interacts with CtBP and p300 in
mesenchymal lung tumor cells. Protein extracts from the indicated cell
lines were used for ZEB1 or control (IgG) immunoprecipitation, followed
by Western blot using the indicated antibodies. The arrowheads indicate
the position of each protein. XT, cell extract; ø, empty lane.
Additional file 4: Figure S4. ZEB1 is induced rapidly upon TGF-β
stimulation. H2122 cells were stimulated with 10 ng/ml TGF-β for the
indicated time points, after which the cells were lysed for RNA preparation
followed by reverse transcription. The cDNA was amplified by real-time PCR
using probes specific for ZEB1, SNAIL, or an internal control. Data show
means ± s.d. (n = 4) of mRNA expression ratios between TGF-β treated and
non-treated conditions.
Additional file 5: Figure S5. Efficiency of siRNA or shRNA knockdown.
(A) Efficiency of GLUT3 or GLUT1 siRNA knockdown. SW1573 cells were
transfected with one of three different siRNAs to target GLUT3, two to
target GLUT1, or a control (ctl) siRNA, or were left untransfected (–).
Seventy-two hours later, the cells were lysed for RNA preparation
followed by reverse transcription. The cDNA was amplified by real-time
PCR using probes specific for the indicated genes or GAPDH as an
internal control. Data show the percentage of mRNA expression relative
to the non-transfected condition (set to 100%). (B) Efficiency of GLUT3
siRNA knockdown. SW1573 cells were transfected with one of three
different siRNAs to target GLUT3, a control (ctl) siRNA, or were left
untransfected (–). Seventy-two hours later, the cells were lysed with RIPA
buffer to prepare protein extracts and to analyze the expression of GLUT3
by Western blot. (C) GLUT3 or GLUT1 knockdown does not affect the
number of dead cells. SW1573 cells were transfected with control (ctl)
siRNA, each of three different siRNAs to decrease GLUT3, or each of two
siRNAs to decrease GLUT1, as indicated. One hundred forty-four hours
later, dead cells were counted by trypan blue exclusion (n = 3). (D) Efficiency
of GLUT3 shRNA stable knockdown. SW1573 cells stably expressing ctl or
GLUT3 shRNAs (in the indicated vectors) were lysed (left panel) with RIPA
buffer to prepare protein extracts and to analyze the expression of GLUT3
by Western blot, or (right panel) for RNA preparation followed by reverse
transcription. The cDNA was amplified by real-time PCR using probes
specific for GLUT3 or GAPDH as an internal control. Data show the
percentage of GLUT3 mRNA expression relative to the control (ctl) shRNA
expressing cells (set to 100%). *n.s., non-specific.
Additional file 6: Figure S6. GLUT3 knockdown leads to diminished
vimentin expression. SW1573 cells stably expressing a control (ctl) orGLUT3 shRNA were lysed for RNA preparation followed by reverse
transcription. The cDNA was amplified by real-time PCR using probes
specific for the indicated genes or internal controls. Data show means ± s.d.
(n = 3) of mRNA expression relative to the condition with the least amount
of mRNA for each gene (set to 1).
Additional file 7: Figure S7. Generation of H727 cells stably expressing
GLUT3. (A) Stable expression of GLUT3. (Left) Parental H727 cells or H727
cells stably expressing a control (ctl) plasmid or a GLUT3 cDNA were
lysed with RIPA buffer to prepare protein extracts and to analyze the
expression of GLUT3 (or β-tubulin as loading control) by Western blot.
(Right) Parental or GLUT3-expressing H727 cells were stained to analyze
the expression of GLUT3 by immunocytochemistry (ICC). Scale bar,
100 μm. (B) Ectopic GLUT3 expression does not affect cell proliferation in
high glucose concentrations. H727 cells, either parental or stably expressing
a control (ctl) plasmid or a GLUT3 cDNA, were cultured in high glucose (glc)
concentrations for 4 days, after which live cells were counted by trypan blue
exclusion (n = 7).
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